For the readers interested in the stock health of Cellectar Biosciences Inc. (CLRB). It is currently valued at $2.48. When the transactions were called off in the previous session, Stock hit the highs of $2.98, after setting-off with the price of $2.35. Company’s stock value dipped to $2.235 during the trading on the day. When the trading was stopped its value was $2.30.
Recently in News on February 10, 2021, Cellectar to Present at BIO CEO & Investor Digital Conference. Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference to be held from February 16-18, 2021. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Cellectar Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.98 on 02/11/21, with the lowest value was $1.65 for the same time period, recorded on 01/28/21.
Cellectar Biosciences Inc. (CLRB) full year performance was -8.82%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cellectar Biosciences Inc. shares are logging -25.53% during the 52-week period from high price, and 145.54% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $3.33.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 5769837 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cellectar Biosciences Inc. (CLRB) recorded performance in the market was 19.23%, having the revenues showcasing 121.43% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 106.04M, as it employees total of 8 workers.
Market experts do have their say about Cellectar Biosciences Inc. (CLRB)
During the last month, 5 analysts gave the Cellectar Biosciences Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.65, with a change in the price was noted +1.27. In a similar fashion, Cellectar Biosciences Inc. posted a movement of +104.96% for the period of last 100 days, recording 1,672,572 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CLRB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Technical breakdown of Cellectar Biosciences Inc. (CLRB)
Raw Stochastic average of Cellectar Biosciences Inc. in the period of last 50 days is set at 72.22%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 62.38%. In the last 20 days, the company’s Stochastic %K was 75.63% and its Stochastic %D was recorded 85.21%.
Bearing in mind the latest performance of Cellectar Biosciences Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 19.23%. Additionally, trading for the stock in the period of the last six months notably improved by 81.02%, alongside a downfall of -8.82% for the period of the last 12 months. The shares increased approximately by 19.23% in the 7-day charts and went down by 22.77% in the period of the last 30 days. Common stock shares were driven by 121.43% during last recorded quarter.